Pd35-07 prostate Cancer Risks in Male Brca1/2 Pathogenic Variant Carriers

Abstract

METHODS: 553 prostate biopsies (2008)(2009)(2010)(2011)(2012)(2013) were performed at our institute. 22 patients refused biopsy. We investigated incidence and severity of PCa in 203 men diagnosed with hypogonadism (T 350 ng/dl). 42 men opted for and 162 against TRT. Biopsies were performed when indicated according to EAU guidelines.RESULTS: In T-treated patients, 42 men (20.7% of the hypogonadal group) underwent a prostate biopsy. 7/42 (16.7%) biopsies were positive. Gleason score was 6 in 5 (71.4%) and >6 in 2 (28.6%) patients. The predominant Gleason score was 3 in all 7 patients (100%). Tumor grade was II in 6 (85.7%) and II-III in 1 (14.3%) patient.In untreated hypogonadal men, 162 men (79.4% of the hypogonadal group) underwent a prostate biopsy. 84/162 (51.9%) biopsies were positive. Gleason score was 6 in 34 (40.5%) and >6 in 50 (59.5%) patients. The predominant Gleason score was 3 in 65 (77.4%), 4 in 17 (20.2%) and 5 in 2 (2.4%) patients. Tumor grade was II in 35 (41.7%), II-III in 10 (11.9%), III in 34 (40.5%) and IV in 5 (6.0%) patients.CONCLUSIONS: Testosterone treatment in hypogonadal men does not increase incidence or severity of PCa in comparison to an untreated hypogonadal control group. Hypogonadism did not protect against prostate cancer. Protective role of TRT against PCa must be discussed and considered in larger studies.